La presente se caracteriza por un método para el tratamiento de un paciente diagnosticado o con riesgo de desarrollar un desorden inmunoinflamatorio por la administración de un SSRI o análogo o metabolito del mismo y opcionalmente un corticosteroide u otro compuesto al paciente. La presente asimismo se caracteriza por una composición farmacéutica que contiene un SSRI o análogo o metabolito del mismo y un corticosteroide u otro compuesto para el tratamiento o prevención de un desorden inmunoinfla...

COMPRENDE UN PORTADOR FARMACEUTICAMENTE ACEPTABLE Y UN BRONCODILATADOR EFECTIVO A PARTIR DE UNA MEZCLA DE 10 A 90 PARTES EN PESO DE BRAZOSIN O LA SAL O EL ACIDO FARMACEUTICAMENTE ACEPTABLES DE LA ADICION DEL ACIDO Y DE 90 A 10 PARTES POR PESO DE PIRBUTEROL O LA SAL CONSECUENTE DE UN ACIDO FARMACEUTICAMENTE ACEPTABLE. TIENE UTILIDAD EN MEDICINA COMO REBAJADOR DE LOS TEJIDOS BRONQUIALES EN LOS MAMIFEROS ESPECIALMENTE PARA EL TRATAMIENTO DE LAS BRONCOCONSTRICCIONES.

PURPOSE: To reduce adverse effects of a selective 2-sympathomimetic bronchodilator useful for curing obstructive or inflammatory air duct diseases especially asthma and improve safety for uses in high doses or long periods. CONSTITUTION: A medicinal composition capable of avoiding improving or controlling occurrence of adverse effects harmful to the air duct especially turning to the worse of states of basic diseases and withdrawing or reducing of pulmonary functions by blending a selective 2-sy...

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a bronchodilating effective amount of a mixture of from 10 to 90 parts by weight of prazosin or a pharmaceutically acceptable acid addition salt thereof and from 90 to 10 parts by weight of pirbuterol or a pharmaceutically acceptable acid addition salt thereof.These compositions are useful for relaxing bronchial tissue in mammals especially for treatment of bronchoconstrictions.(From EP0222575 A1)

A method and composition are disclosed utilizing the pure (-) isomer of pirbuterol which is a potent bronchodilator and a potent cardiovascular stimulant with reduced adverse effects having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.

A method and composition are disclosed utilizing the pure (+) isomer of pirbuterol which is a potent bronchodilator and a potent cardiovascular stimulant with reduced adverse effects having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.

Improved antiinflammatory salts of piroxicam with antidepressant doxepin with bronchodilator pirbuterol or isoproterenol with H2-antagonist inhibitor 2-guanidino-4-(2-methyl-4-imidazolyl)thiazole with pyridoxine a member of the vitamin B6 complex or with antihypertensive trimazosin.(From US4567179 A)